Real-world outcomes after switching to faricimab in treatment-resistant diabetic macular edema: A 1-year observational study with choroidal thickness assessment

Ryo Tomemori, Hidetsugu Mori, Mari Tanaka, Tatsunori Kiriishi, Masatoshi Omi, Yuki Hattori, Shimpei Oba, Masayuki Ohnaka · 2026

Read Real-world outcomes after switching to faricimab in treatment-resistant diabetic macular edema: A 1-year observational study with choroidal thickness assessment by Ryo Tomemori, Hidetsugu Mori, Mari Tanaka, Tatsunori Kiriishi, Masatoshi Omi, Yuki Hattori, Shimpei Oba, Masayuki Ohnaka (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0351168.txt.

Description

Ryo Tomemori and colleagues reviewed patients whose diabetic eye swelling had resisted standard injections and who switched to a newer drug, faricimab. Swelling at the centre of vision blurs sight in diabetes, and about four in ten cases resist first line care. Records covered twenty eight eyes from nineteen patients, tracked a year before and a year after the switch.

Centre thickness fell by close to one third, and over half of eyes reached a dry centre mark at one year. Injections grew more frequent after the switch, while measured vision barely changed. Deeper layer thickness stayed steady. Switching can dry the retina, the data suggest, even when vision gains lag behind anatomy.

Catalog record

CREATORRyo Tomemori, Hidetsugu Mori, Mari Tanaka, Tatsunori Kiriishi, Masatoshi Omi, Yuki Hattori, Shimpei Oba, Masayuki Ohnaka
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE38284
LICENSECC_BY
RIGHTSCC BY
SOURCEPLOS

Source: https://doi.org/10.1371/journal.pone.0351168

Browse the full library · About the Tower of Babel